Message: file_get_contents(https://...@gmail.com&api_key=61f08fa0b96a73de8c900d749fcb997acc09): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests
Beirne B. Carter Center for Immunology Research, University of Virginia, Charlottesville, VA, USA.
Published: September 2024
AI Article Synopsis
* It was previously thought that CLL suppresses the immune system and allows MCC to develop, but new findings suggest that MCC may actually help CLL persist.
* The research indicates that a factor produced by MCC, known as macrophage migration inhibitory factor (MIF), stimulates certain receptors that help maintain CLL, and this might explain why patients' blood cell counts normalize after MCC treatment.
Article Abstract
While concurrent diagnoses of Merkel cell carcinoma (MCC) and other cancers, like Chronic lymphocytic leukemia (CLL), are rare, patients with MCC have a 30-fold higher incidence of CLL. While these increases have been attributed to the ability of CLL to suppress immune responses allowing for the emergence of MCC, here we found evidence that MCC could support the persistence of CLL. Using single cell sequencing approaches and computational analyses of MCC and CLL from a patient where both cancers were present in the same lymph node, we found that production of macrophage migration inhibitory factor (MIF) by MCC could promote the persistence of CLL through stimulation of CD74 and CXCR4. These results may explain why blood cell counts rapidly normalized after treatment for MCC and were maintained at normal levels despite the absence of treatment for CLL.
